About the Authors

Alastair J. Noyce

a.noyce@ucl.ac.uk

Affiliations Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, London, United Kingdom, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom

Anna Nagy

Affiliation Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom

Shami Acharya

Affiliation Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom

Shahrzad Hadavi

Affiliation Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom

Jonathan P. Bestwick

Affiliation Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom

Julian Fearnley

Affiliation The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, United Kingdom

Andrew J. Lees

Affiliation Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, London, United Kingdom

Gavin Giovannoni

Affiliation Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom

Competing Interests

The authors have read the journal's policy and report the following conflicts: AJ Noyce declares the following: consultancy, Élan/Prothena Pharmaceuticals; Grants, Parkinson's UK Innovation Grant (reference number K-1006), and National Institute of Health Research Academic Clinical Fellowship. A Nagy, S Acharya, S Hadavi, JP Bestwick, and J Fearnley declare no competing interests. AJ Lees declares the following: board membership, Novartis, Teva, Meda, Boehringer Ingelheim, GSK, Ipsen, Lundbeck, Allergan, Orion, BIAL, Noscira, Roche; consultancy, Genus; employment, UCH/UCLH; grants/grants pending, PSP Association, Weston Trust–Reta Lila Howard Foundation; speaking fees, Novartis, Teva, Meda, Boehringer Ingelheim, GSK, Ipsen, Lundbeck, Allergan, Orion, BIAL, Noscira, Roche. G Giovannoni declares the following: consultancy fees, Merck-Serono, Biogen-Idec, Ironwood, Genentech, Teva, GSK, Sanofi-Aventis, Novartis, Roche, UCB Pharmaceuticals, Vertex, Eisai, Elan, Fiveprime, Bayer-Schering, Synthon BV, and Genyme; grants/grants pending from Biogen-Idec, Bayer-Schering, GW Pharma, Merck-Serono, Merz, Novartis, Teva, Sanofi-Aventis. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: AJN AJL GG. Performed the experiments: AJN AN SA SH. Analyzed the data: AJN AN SA JPB. Wrote the paper: AJN AN SA SH JPB JF AJL GG.